Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study

INTRODUCTION: Pivotal trials documented glycemic benefits of fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), with no weight gain and low hypoglycemia risk in type 2 diabetes (T2D). This study aimed at assessing effectiveness and patterns of use of iGlarLixi in a re...

Descripción completa

Detalles Bibliográficos
Autores principales: Candido, Riccardo, Modugno, Monica, Larosa, Monica, Rossi, Maria Chiara, Nicolucci, Antonio, Gabellieri, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663199/
https://www.ncbi.nlm.nih.gov/pubmed/36376644
http://dx.doi.org/10.1007/s13300-022-01328-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663199/
https://www.ncbi.nlm.nih.gov/pubmed/36376644
http://dx.doi.org/10.1007/s13300-022-01328-7

Ejemplares similares